Cybrexa Therapeutics Doses the First Patient with CBX-12 Under P-II Study for Treating Ovarian Cancer
Shots:
- Cybrexa has dosed the first patient in P-II study assessing safety, tolerability & effectiveness of CBX-12 (125mg/m^2 or 100mg/m^2, Q21D) for the treatment of Pt-resistant or refractory ovarian cancer
- The P-II builds upon the results from P-I study, showing a response rate of 40% among TOP1-naïve ovarian cancer patients along with a favorable & well-tolerated safety profile. Data was featured at ESMO 2024
- Cybrexa anticipates a P-II trial of CBX-12 for CRC with the NCI in 2025, along with other P-II studies of CBX-12 alone & in combinations for solid tumors. The company’s CBX-15 will enter trials in 2025 focusing solid tumors with monomethyl auristatin E (MMAE) as payload
Ref: Cybrexa Therapeutics | Image: Cybrexa Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
